Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT ID: NCT07213973
Last Updated: 2025-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
40 participants
INTERVENTIONAL
2025-12-14
2028-03-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
NCT03569371
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT06921850
Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa
NCT05040698
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Povorcitinib Dose A
Participants will receive povorcitinib dose A for 54 weeks.
Povorcitinib
Oral; Tablet
Povorcitinib Dose B
Participants will receive povorcitinib dose B for 54 weeks.
Povorcitinib
Oral; Tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Povorcitinib
Oral; Tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body weight ≥ 30 kg at both screening and baseline visits.
* Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit.
* Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits.
* HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits.
* Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS).
* Agreement to use contraception.
* Willing and able to comply with the study protocol and procedures.
Exclusion Criteria
* Women who are pregnant (or who are considering pregnancy) or breastfeeding.
* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
* Laboratory values outside of the protocol-defined ranges.
12 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Incyte Medical Monitor
Role: STUDY_DIRECTOR
Incyte Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama At Birmingham
Birmingham, Alabama, United States
Medical Dermatology Specialists Phoenix
Phoenix, Arizona, United States
Saguaro Dermatology
Phoenix, Arizona, United States
Rady Children'S Hospital-San Diego
San Diego, California, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
Skin Research of South Florida, Llc
Miami, Florida, United States
Trueblue Clinical Research
Tampa, Florida, United States
Marietta Dermatology the Skin Cancer Center Marietta
Marietta, Georgia, United States
Advanced Medical Research Pc
Sandy Springs, Georgia, United States
Endeavor Health Medical Group
Skokie, Illinois, United States
Dermatology Skin Cancer Center Leawood
Leawood, Kansas, United States
Equity Medical
Bowling Green, Kentucky, United States
Johns Hopkins Oncology Center
Baltimore, Maryland, United States
Kindred Hair and Skin Center
Marriottsville, Maryland, United States
Boston Childrens Hospital
Boston, Massachusetts, United States
Oakland Hills Dermatology Pc
Auburn Hills, Michigan, United States
Wayne State University Physician Group Dermatology
Dearborn, Michigan, United States
Revival Research Institute, Llc Troy
Troy, Michigan, United States
Washington University
St Louis, Missouri, United States
Boeson Research Missoula 2825 Fort Missoula Rd
Missoula, Montana, United States
University of New Mexico Hospital
Albuquerque, New Mexico, United States
Geisinger Medical Center
Danville, Pennsylvania, United States
Bellaire Dermatology Associates Bda
Bellaire, Texas, United States
Acrc Trials/Innovative Dermatology
Plano, Texas, United States
Texas Dermatology Research Center
Plano, Texas, United States
Beacon Dermatology
Calgary, Alberta, Canada
Dermcare Clinic
Mississauga, Ontario, Canada
York Dermatology Center
Richmond Hill, Ontario, Canada
The Hospital For Sick Children
Toronto, Ontario, Canada
Skincare Studio Dermatology Centre
St. John's, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INCB054707-211
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.